Zdrowie i gospodarka · 08/02/1999

FDA Releases Draft Guidance for Extracorporeal Shock Wave Lithotripters

The Food and Drug Administration (FDA) has published a draft guidance outlining the required information for premarket notifications for extracorporeal shock wave lithotripters intended to treat kidney and ureteral stones, pending a final rule reclassifying these devices from class III to class II.